Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review

BACKGROUND: Everolimus, an immunosuppressant, is approved for the treatment of advanced renal cell carcinoma, metastatic hormone receptor-positive breast cancer, and pancreatic neuroendocrine tumors (P-NETs) but has been reported to be related to hepatitis B reactivation. Here, we present the first...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Shih-Chun, Tsai, Chun-Yi, Liu, Keng-Hao, Wang, Shang-yu, Hsu, Jun-Te, Yeh, Ta-Sen, Yeh, Chun-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047461/
https://www.ncbi.nlm.nih.gov/pubmed/33868173
http://dx.doi.org/10.3389/fendo.2021.639967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047461/
https://www.ncbi.nlm.nih.gov/pubmed/33868173
http://dx.doi.org/10.3389/fendo.2021.639967

Ejemplares similares